Asia Green Biotechnology Corp. (ASIA) AI Stock Analysis

• Market Cap: C$543.71K
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.20
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 36,247,100
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.04
• Price to Book (P/B): -0.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 31 Underperform
• Price Target: ―

The overall stock score is significantly impacted by the poor financial performance due to severe financial distress, lack of revenue, and high operational losses. The stable technical indicators suggest no immediate market trend, and the negative P/E ratio raises valuation concerns. The absence of earnings call and corporate events data means these factors have no significant influence on the score.

Positive Factors

Innovative Product Offering

ASIA's focus on innovative plant-based technologies positions it well in sustainable agriculture, potentially driving long-term demand.

Strategic Partnerships

Strategic partnerships for R&D and licensing can enhance ASIA's market reach and innovation capabilities, supporting growth.

Sustainable Agriculture Focus

ASIA's commitment to sustainable agriculture aligns with global trends, potentially attracting eco-conscious customers and partners.

Negative Factors

Severe Financial Distress

The lack of revenue and high operational losses indicate severe financial distress, threatening long-term viability without a turnaround.

Negative Cash Flow

Persistent negative cash flow suggests ongoing liquidity issues, limiting ASIA's ability to invest in growth or sustain operations.

Weak Balance Sheet

A weak balance sheet with high leverage poses solvency risks, potentially hampering ASIA's financial stability and growth prospects.

Asia Green Biotechnology Corp. Business Overview & Revenue Model

Company Description

Asia Green Biotechnology Corp., an early stage international bio-technology company, focuses on the development, evaluation, testing, application, and supply of products derived from proprietary organic hybridization technology in Asia. The company focuses on planting, growing, and harvesting new and valuable strains of hemp and related crops. It has an agreement with Pathway Rx Inc. and PNW Biosciences Inc. for the clinical development and commercialization of the cannabis sativa varieties for prevention and treatment of COVID-19 and other infectious diseases. The company was formerly known as Asia Cannabis Corp. and changed its name to Asia Green Biotechnology Corp. in April 2020. Asia Green Biotechnology Corp. was incorporated in 2017 and is based in Calgary, Canada.

How the Company Makes Money

Asia Green Biotechnology Corp. makes money through the sale of its biotech agricultural products, including genetically modified seeds, biopesticides, and biofertilizers to farmers and agricultural companies. The company also generates revenue by licensing its proprietary biotechnology innovations to other agricultural firms and entering into strategic partnerships for research and development. Additionally, ASIA may receive government grants and subsidies aimed at promoting sustainable agricultural practices, which can contribute to its earnings.

Asia Green Biotechnology Corp. Financial Statement Overview

Summary

Asia Green Biotechnology Corp. is experiencing severe financial distress with no revenue, high losses, negative equity, and significant cash outflows. The firm’s financials highlight substantial operational and financial challenges, with no current pathway to profitability or growth evident from the data.

Income Statement

The company has reported no revenue over the assessed periods, leading to negative net income and EBIT margins. This indicates a lack of revenue generation ability or early-stage operations. The firm's profitability margins are negative, reflecting ongoing losses and operational challenges.

Balance Sheet

The balance sheet is currently weak, with negative stockholders' equity suggesting liabilities exceed assets, indicating financial instability. The debt levels are high compared to equity, which implies significant leverage and potential solvency risks.

Cash Flow

Cash flows are consistently negative, with significant operating cash outflows and no positive free cash flow, signaling cash burn and potential liquidity issues. The company has financed operations through debt and equity but lacks operational cash generation.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-317.98K	23.16K	-179.00K	-523.00K	-553.00K	-687.00K
Net Income	-350.29K	-221.00K	-198.00K	-525.00K	-553.00K	-767.00K
Balance Sheet
Total Assets	7.36K	65.34K	68.18K	116.30K	441.38K	1.05M
Cash, Cash Equivalents and Short-Term Investments	198.00	1.31K	12.40K	67.27K	381.15K	1.02M
Total Debt	237.41K	237.41K	190.70K	150.00K	0.00	0.00
Total Liabilities	666.63K	527.31K	308.98K	193.09K	28.33K	88.95K
Stockholders Equity	-659.27K	-461.98K	-240.80K	-76.79K	413.05K	965.88K
Cash Flow
Free Cash Flow	-2.25K	-36.09K	-125.35K	-463.88K	-640.78K	-670.67K
Operating Cash Flow	-2.25K	-36.09K	-125.35K	-463.88K	-640.78K	-670.67K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	0.00	25.00K	70.48K	150.00K	0.00	1.21M

Asia Green Biotechnology Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBRA	49 Neutral	C$420.72K	-0.31	―	―	―	―
VIBE	47 Neutral	C$647.82K	-0.07	-201.37%	―	32.33%	24.01%
CNTR	40 Underperform	C$289.94K	-1.05	―	―	―	―
ASIA	31 Underperform	C$543.71K	-1.55	―	―	―	―